Literature DB >> 11262217

A whole blood bactericidal assay for tuberculosis.

R S Wallis1, M Palaci, S Vinhas, A G Hise, F C Ribeiro, K Landen, S H Cheon, H Y Song, M Phillips, R Dietze, J J Ellner.   

Abstract

The bactericidal activity of orally administered antituberculosis (anti-TB) drugs was determined in a whole blood culture model of intracellular infection in which microbial killing reflects the combined effects of drug and immune mechanisms. Rifampin (Rif) was the most active compound studied and reduced the number of viable bacilli by >4 logs. Isoniazid (INH), 2 quinolones, and pyrazinamide (PZA) showed intermediate levels of activity. Ethambutol exerted only a bacteristatic effect; amoxicillin/clavulanate was inactive. The combination of INH-Rif-PZA showed strong activity against 11 drug-sensitive isolates (mean, -3.8 log) but no activity against 12 multidrug-resistant (MDR) strains. The combination of levofloxacin-PZA-ethambutol had intermediate bactericidal activity against MDR isolates (mean, -1.2 log) but failed to equal that of INH-Rif-PZA against sensitive isolates (P<.001). The whole blood BACTEC method (Becton Dickinson) may be useful for the early clinical evaluation of new anti-TB drugs and in the management of individual patients.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11262217     DOI： 10.1086/319679

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  49 in total

1.  Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Authors:  Seon-Hee Cheon; Beate Kampmann; Amy G Hise; Manijeh Phillips; Ho-Yeon Song; Katherine Landen; Qing Li; Rhonda Larkin; Jerrold J Ellner; Richard F Silver; Daniel F Hoft; Robert S Wallis
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

3.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

5.  Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity.

Authors:  Ernestas Janulionis; Carolina Sofer; Stephan K Schwander; Denarra Nevels; Barry Kreiswirth; Elena Shashkina; Robert S Wallis
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Authors:  Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

7.  Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Authors:  Claire M Naftalin; Rupangi Verma; Meera Gurumurthy; Qingshu Lu; Matthew Zimmerman; Benjamin Chaik Meng Yeo; Kin Hup Tan; Wenwei Lin; Buduo Yu; Véronique Dartois; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

8.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture.

Authors:  Ernestas Janulionis; Carolina Sofer; Ho-Yeon Song; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 10.  Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence.

Authors:  Issar Smith
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.